Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00945958 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT00945958: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Sun Pharma Advanced Research Company Limited.
NCT00945958 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 161 participants, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00945958, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.
Primary Outcome
Subjects with treatment emergent adverse events
Conditions Studied
Interventions
- DRUG SPARC0913
Study Locations (1)
North Carolina
- SPARC study site - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
What the finished NCT00945958 record still lists
NCT00945958 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (41% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which SPARC0913 is the first listed.
NCT00945958 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00945958 about?
NCT00945958 is a clinical study titled "Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension". The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a peri...
What is the current status of trial NCT00945958?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2010-11. Estimated completion is 2012-06.
What conditions does trial NCT00945958 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT00945958?
The interventions under investigation include: SPARC0913 (DRUG).
Who is sponsoring clinical trial NCT00945958?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00945958 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00945958's enrollment target sits among peer trials
161 30th of 54 higher than 25 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia